Poseida Therapeutics, Inc.

DB:2RZ Stock Report

Market Cap: €879.0m

Poseida Therapeutics Valuation

Is 2RZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2RZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 2RZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 2RZ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2RZ?

Key metric: As 2RZ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 2RZ. This is calculated by dividing 2RZ's market cap by their current revenue.
What is 2RZ's PS Ratio?
PS Ratio6.1x
SalesUS$150.86m
Market CapUS$917.16m

Price to Sales Ratio vs Peers

How does 2RZ's PS Ratio compare to its peers?

The above table shows the PS ratio for 2RZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.4x
FYB Formycon
14.9x32.0%€905.8m
BIO3 Biotest
1.4x3.6%€1.3b
HPHA Heidelberg Pharma
12.5x16.6%€105.8m
2INV 2invest
8.7xn/a€67.3m
2RZ Poseida Therapeutics
6.1x8.6%€917.2m

Price-To-Sales vs Peers: 2RZ is good value based on its Price-To-Sales Ratio (6.1x) compared to the peer average (9.4x).

Price to Sales Ratio vs Industry

How does 2RZ's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIO3 Biotest
1.4x3.6%US$1.39b
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
2RZ 6.1xIndustry Avg. 8.2xNo. of Companies7PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 2RZ is good value based on its Price-To-Sales Ratio (6.1x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is 2RZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2RZ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.1x
Fair PS Ratio3.6x

Price-To-Sales vs Fair Ratio: 2RZ is expensive based on its Price-To-Sales Ratio (6.1x) compared to the estimated Fair Price-To-Sales Ratio (3.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2RZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€8.91
€8.98
+0.8%
5.3%€9.45€8.51n/a2
Dec ’25€8.67
€8.98
+3.5%
5.3%€9.45€8.51n/a2
Nov ’25€2.18
€12.89
+490.8%
30.9%€18.42€9.21n/a3
Oct ’25€2.53
€12.54
+394.8%
30.9%€17.91€8.96n/a3
Sep ’25€2.47
€12.81
+418.3%
30.9%€18.30€9.15n/a3
Aug ’25€2.99
€12.91
+332.2%
30.9%€18.44€9.22n/a3
Jul ’25€2.64
€12.94
+390.4%
30.9%€18.48€9.24n/a3
Jun ’25€2.59
€12.94
+399.5%
30.9%€18.48€9.24n/a3
May ’25€2.10
€13.14
+527.1%
30.9%€18.78€9.39n/a3
Apr ’25€2.90
€12.80
+341.4%
30.9%€18.29€9.14n/a3
Mar ’25€3.60
€12.88
+257.7%
30.9%€18.40€9.20n/a3
Feb ’25€3.08
€12.88
+318.1%
30.9%€18.40€9.20n/a3
Jan ’25€3.10
€12.71
+310.1%
30.9%€18.16€9.08n/a3
Dec ’24€2.42
€11.26
+365.3%
21.9%€13.79€7.35€8.674
Nov ’24€1.88
€11.55
+514.5%
21.9%€14.15€7.54€2.184
Oct ’24€2.28
€11.59
+408.2%
21.9%€14.19€7.57€2.534
Sep ’24€1.89
€10.75
+468.8%
21.7%€13.67€7.29€2.475
Aug ’24€1.55
€12.35
+696.6%
19.2%€15.66€9.21€2.995
Jul ’24€1.50
€12.35
+723.1%
19.2%€15.66€9.21€2.645
Jun ’24€2.10
€12.35
+487.9%
19.2%€15.66€9.21€2.595
May ’24€2.16
€12.59
+483.0%
19.2%€15.98€9.40€2.105
Apr ’24€2.82
€12.59
+346.6%
19.2%€15.98€9.40€2.905
Mar ’24€5.30
€14.03
+164.7%
33.5%€22.75€9.48€3.605
Feb ’24€5.70
€13.95
+144.8%
33.5%€22.63€9.43€3.085
Jan ’24€4.82
€14.24
+195.4%
37.6%€23.17€9.65€3.104
Dec ’23€4.30
€14.24
+231.2%
37.6%€23.17€9.65€2.424

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 13:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Poseida Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Justin ZelinBTIG
Jennifer KimCantor Fitzgerald & Co.